Centessa Pharmaceuticals Unveils ORX750 Data at AAN
In an exciting announcement, Centessa Pharmaceuticals plc (Nasdaq: CNTA), a pioneer in developing transformative medications, has shared that groundbreaking data from the Phase 1 clinical trial of ORX750 will be showcased at the American Academy of Neurology's 2025 Annual Meeting. Set to occur from April 5-9 in San Diego, this event represents a significant opportunity for the company to present its findings on a highly selective orexin receptor 2 (OX2R) agonist, aimed at treating various sleep-wake disorders.
About ORX750 and Its Clinical Significance
ORX750 is currently under investigation for its potential benefits for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). The ongoing Phase 2a clinical trial, known as CRYSTAL-1, further explores its efficacy among participants suffering from these conditions. This novel therapeutic approach is gaining attention due to its targeted mechanism, which may revolutionize treatment protocols for individuals battling debilitating sleep disorders.
Poster Presentation Highlights
Details regarding the poster presentation are as follows:
- Title: Phase 1 Clinical Data with Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Participants
- Abstract Number: 2277
- Presenter: Deborah Hartman, PhD, Global Scientific Head of the Orexin Program
- Session Date and Time: Saturday, April 5, 2025, from 11:45 AM to 12:45 PM PT
Centessa Pharmaceuticals at AAN 2025
Centessa’s commitment to addressing significant medical challenges is evident in its active involvement at the AAN 2025. Attendees are invited to visit booth number 627 to learn more about Centessa's innovative approaches to sleep-wake disorders and other neurological conditions.
Accessing Conference Materials
For those unable to attend in person, the abstracts from the AAN conference will be accessible on the official conference website post-event. Additionally, Centessa plans to make their poster available directly on their website after the presentation wraps up, ensuring that all interested parties can review their findings.
Centessa Pharmaceuticals: Pioneering Innovative Treatments
Centessa Pharmaceuticals is embarking on a mission to create groundbreaking therapies for complex conditions. Their innovative OX2R agonists aim to uplift patients experiencing sleep disturbances due to narcolepsy and other neurodegenerative conditions. Additionally, Centessa's research anticipates applications for their treatments to address impaired attention, cognitive deficits, fatigue, and symmetric symptoms that often accompany these disorders. The company is also exploring its advanced immuno-oncology pipeline using its proprietary LockBody technology platform.
Connecting with Centessa Pharmaceuticals
For investors and other stakeholders interested in learning more about Centessa’s groundbreaking work, Kristen K. Sheppard, SVP of Investor Relations, can be reached at investors@centessa.com. Staying informed is key as Centessa continues to push boundaries in pharmaceutical innovation.
Frequently Asked Questions
What is ORX750 and its purpose?
ORX750 is a highly selective orexin receptor 2 (OX2R) agonist being developed to treat sleep-wake disorders such as narcolepsy and idiopathic hypersomnia.
Where will the Phase 1 data be presented?
The Phase 1 clinical data for ORX750 will be presented at the American Academy of Neurology's Annual Meeting in San Diego.
When is the presentation scheduled?
The presentation is scheduled for Saturday, April 5, 2025, from 11:45 AM to 12:45 PM PT.
How can I learn more about Centessa Pharmaceuticals?
Interested parties can visit Centessa’s booth at AAN 2025 or check their website following the poster presentation.
Who should I contact for investor inquiries?
Kristen K. Sheppard can be contacted for investor relations inquiries via email at investors@centessa.com.
